has announced that the FDA has granted fast track designation for Spheramine
for the treatment of advanced Parkinson’s disease. Spheramine consists
of normal, human retinal pigment epithelial cells adhered to spherical microscopic
has announced that patient enrollment has begun in the final Phase III trial
of its lead product candidate, doripenem. Doripenem, a broad-spectrum antibiotic,
is a new member of the carbapenem class of beta-lactam antibiotics. This trial
will compare the safety and efficacy of intravenous doripenem with that of
intravenous imipenem in patients with ventilator-associated pneumonia.
PTC Therapeutics has
announced the initiation of a Phase I clinical trial of PTC124 to evaluate
the drug’s safety, tolerability, and pharmacokinetic profile. PTC124 is a
small-molecule drug that is being investigated initially as a treatment for
cystic fibrosis and Duchenne muscular dystrophy.